Herrera-Acosta Enrique, Garriga-Martina Gustavo Guillermo, Suárez-Pérez Jorge Alonso, Martínez-García Eliseo, Herrera-Ceballos Enrique
Department of Dermatology, Hospital Clínico Virgen de la Victoria, Malaga, Spain.
Dermatol Ther. 2020 Nov;33(6):e14202. doi: 10.1111/dth.14202. Epub 2020 Sep 7.
There is a lack of real practice studies comparing ustekinumab and ixekizumab effectiveness and safety. The main aim of this study was to compare the effectiveness and safety of both drugs used to treat moderate-to-severe psoriasis patients over 52 weeks. The secondary objective was to identify which clinical variables could have an impact on its effectiveness. A retrospective observational study was carried out, comparing the first 28 patients treated with ustekinumab after its commercialization was compared to the first 35 patients treated with ixekizumab. Although a higher level of skin clearance was achieved with ixekizumab with a PASI 90 and 100 response of 54.3% and 40% compared to 42.9% and 25% for ustekinumab, these differences were not statistically significant. Ixekizumab achieved a higher PASI 90 response in those patients with BMI > 27 (slightly overweight), which was statistically significant (P = .024). Ustekinumab had a greater survival at 52 weeks than ixekizumab, with a trend towards statistical significance (P = .052). Ixekizumab achieved higher skin clearance rates (PASI 90 and 100 response) than ustekinumab, with no statistically significant differences. However, ixekizumab should be specially considered in overweight patients.
缺乏比较优特克单抗和司库奇尤单抗有效性及安全性的实际应用研究。本研究的主要目的是比较这两种药物用于治疗中度至重度银屑病患者52周的有效性和安全性。次要目标是确定哪些临床变量可能会对其有效性产生影响。开展了一项回顾性观察研究，将优特克单抗商业化后治疗的前28例患者与司库奇尤单抗治疗的前35例患者进行比较。尽管司库奇尤单抗实现了更高的皮肤清除率，达到PASI 90和PASI 100反应的比例分别为54.3%和40%，而优特克单抗为42.9%和25%，但这些差异无统计学意义。司库奇尤单抗在体重指数（BMI）>27（略超重）的患者中实现了更高的PASI 90反应，具有统计学意义（P = 0.024）。优特克单抗在52周时的留存率高于司库奇尤单抗，有统计学意义的趋势（P = 0.052）。司库奇尤单抗实现了比优特克单抗更高的皮肤清除率（PASI 90和PASI 100反应），但无统计学显著差异。然而，超重患者应特别考虑使用司库奇尤单抗。
